Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Enzalutamide · 1 trial · 1 indication
MTD will be determined by testing increasing doses of everolimus with standard dose enzalutamide in 3-patient dose escalation cohorts. The MTD is defined as the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity (DLT) during 1 cycle (28 days) of therapy, assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
PSA response will be measured by the percent decreased from the reported baseline value. The proportion of patients with documented PSA decreases of 50% and 85% in PSA levels will be reported separately.
Evaluate the safety of the combination per CTCAE v4.0, every 4 weeks from date of first study treatment until the date of documented progression, up to 24 months.
Levels of everolimus in blood samples will be collected from patients at selected timepoints prior to dosing during the first 3 cycles of treatment.
| Arm | Type | Description |
|---|---|---|
| Everolimus and Enzalutamide | EXPERIMENTAL | Dose Escalation Phase (18 patients): 3-6 patients will be treated at each dose level until the Maximum Tolerated Dose (MTD) is determined. * Everolimus: Orally (PO) once daily (dose to be determined; * Enzalutamide: 160mg (four 40mg capsules) PO continuous daily dosing. Dose Expansion Phase (23 patients): Everolimus and Enzalutamide to be administered using the MTD determined in the dose escalation phase. |
| Name | Type | Description |
|---|---|---|
| Everolimus | DRUG | - |
| Enzalutamide | DRUG | - |
Inclusion Criteria: KEY POINTS: 1. Adenocarcinoma of the prostate confirmed histologically. 2. Metastatic disease confirmed by biopsy or imaging studies. 3. Castrate-resistant prostate cancer (i.e., progression of prostate cancer while receiving standard androgen ablation therapy, orchiectomy or l...
Top 20 of 53 competitors
Enzalutamide is an investigational small molecule being studied for the treatment of prostate cancer, specifically in men with metastatic castrate-resistant prostate cancer. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Enzalutamide is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 1 clinical trials for prostate cancer.
Enzalutamide is in Phase 1 clinical development for prostate cancer. It is an investigational drug, meaning it has not yet received regulatory approval and is still being evaluated in clinical trials to assess its safety and efficacy.
Enzalutamide has one completed Phase 1 clinical trial, identified as NCT02125084, titled "Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer." This trial enrolled 38 male participants aged 18 years and older in the United States and was not randomized or blinded.
Enzalutamide is not known to have any alternative names. It is a distinct small molecule being developed by Novartis AG for the treatment of prostate cancer, and no other names for this drug have been reported.